Bio-Gene Technology Ltd
ASX:BGT
Intrinsic Value
Bio-Gene Technology Ltd. is a development company enabling the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. [ Read More ]
The intrinsic value of one BGT stock under the Base Case scenario is 0.013 AUD. Compared to the current market price of 0.059 AUD, Bio-Gene Technology Ltd is Overvalued by 79%.
Valuation Backtest
Bio-Gene Technology Ltd
Run backtest to discover the historical profit from buying and selling BGT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bio-Gene Technology Ltd
Current Assets | 4.1m |
Cash & Short-Term Investments | 3.2m |
Receivables | 557.8k |
Other Current Assets | 273.5k |
Non-Current Assets | 234.4k |
PP&E | 12.8k |
Intangibles | 221.7k |
Current Liabilities | 572.9k |
Accounts Payable | 454.9k |
Accrued Liabilities | 118k |
Non-Current Liabilities | 28.7k |
Other Non-Current Liabilities | 28.7k |
Earnings Waterfall
Bio-Gene Technology Ltd
Revenue
|
761.1k
AUD
|
Operating Expenses
|
-3.4m
AUD
|
Operating Income
|
-2.6m
AUD
|
Other Expenses
|
250
AUD
|
Net Income
|
-2.6m
AUD
|
Free Cash Flow Analysis
Bio-Gene Technology Ltd
BGT Profitability Score
Profitability Due Diligence
Bio-Gene Technology Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Bio-Gene Technology Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
BGT Solvency Score
Solvency Due Diligence
Bio-Gene Technology Ltd's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
Bio-Gene Technology Ltd's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BGT Price Targets Summary
Bio-Gene Technology Ltd
Shareholder Return
BGT Price
Bio-Gene Technology Ltd
Average Annual Return | 8.71% |
Standard Deviation of Annual Returns | 59.72% |
Max Drawdown | -100% |
Market Capitalization | 11.9m AUD |
Shares Outstanding | 201 362 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bio-Gene Technology Ltd. is a development company enabling the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-29. The Company’s principal activity is to develop and commercialize insecticide products. The company is focused on enabling novel insecticides to address the global problem of insecticide resistance and toxicity. Its novel platform technology is based on naturally occurring beta-triketones. The Company’s lead beta-triketone insecticide products include Flavocide and Qcide. Flavocide is a synthetically produced nature-identical compound. Testing of Flavocide has been undertaken and continues to be performed by both government research laboratories as well as by commercial collaborators. Qcide natural oil with high levels of tasmanone. The oil is extracted from the leaves of the Gympie Messmate, by utilizing a steam distillation process.
Contact
IPO
Employees
Officers
The intrinsic value of one BGT stock under the Base Case scenario is 0.013 AUD.
Compared to the current market price of 0.059 AUD, Bio-Gene Technology Ltd is Overvalued by 79%.